Vertex Pharmaceuticals (VRTX) Acquisitions (2009 - 2019)

Vertex Pharmaceuticals (VRTX) posted quarterly Acquisitions of $908.4 million for Q4 2019, up 939.07% quarter-over-quarter from $87.4 million in Q1 2009.

Vertex Pharmaceuticals (VRTX) Acquisitions (2009 - 2019) Analysis & Trends

Vertex Pharmaceuticals' Acquisitions history runs 2 years deep, the most recent figure standing at $908.4 million for Q4 2019.

  • In Q4 2019, Acquisitions changed N/A year-over-year to $908.4 million; the TTM figure through Dec 2022 stood at $908.4 million (changed 0.0% YoY), while the FY2022 annual figure was $295.9 million, changed N/A from the prior year.
  • Acquisitions for Q4 2019 stood at $908.4 million, up from $87.4 million in the prior quarter.
  • The five-year high for Acquisitions was $908.4 million in Q4 2019, with the low at $908.4 million in Q4 2019.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Acquisitions (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn -
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn -
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn -
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn -
7 Royalty Pharma 33.72 Bn 35.84 Bn - -
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn -
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn -
10 Roivant Sciences 26.16 Bn 26.85 Bn 1.16 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2019 908.38 Mn
Mar 31, 2009 87.42 Mn